Wearable Defibrillator Protects Children at Risk
|
By HospiMedica International staff writers Posted on 28 Dec 2015 |
A novel wearable defibrillator now offers an advanced protection and monitoring option for children at risk of sudden cardiac arrest.
The LifeVest is a wearable defibrillator, which unlike an implantable cardioverter defibrillator (ICD) is worn on the body (under clothing), rather than implanted into it. Weighing less than one kilogram, the device consists of two main components: an electrode belt and vest-like garment that surround the patient’s chest, and a monitor that the patient wears around the waist. The pediatric device is intended only for children weighing at least 18 kg and with a chest size of 66 cm or more, which is about the size of an average eight year old.
The device continuously monitors the patient's heart using dry, non-adhesive sensing electrodes that detect abnormal heart rhythms. If such a life-threatening cardiac rhythm is detected, the device alerts the patient prior to delivering a shock, thus allowing a conscious patient to postpone the treatment shock. If, on the other hand, the patient is unconscious, the device releases a special gel over the therapy electrodes and delivers an electrical shock to restore normal rhythm.
The LifeVest Wearable Cardioverter Defibrillator is a product of Zoll Medical Corporation (Zoll; Chelmsford, MA, USA), and has been approved by the US Food and Drug Administration (FDA) for children who are at risk for sudden cardiac arrest, but are not candidates for an ICD due to certain medical conditions or lack of parental consent. The device was previously approved in 2001 for patients 18 years of age and older.
“The pediatric medical community is often forced to use adult devices off-label without appropriate labeling or instructions for use in pediatric patients,” said Vasum Peiris, MD, MPH, chief medical officer of pediatrics and special populations in the FDA Center for Devices and Radiological Health (CDRH). “Doctors now have important information that may help them safely prescribe this life-saving device to young patients who may benefit from the device.”
Ventricular fibrillation (VF) and ventricular tachycardia (VT) are life-threatening abnormal heart rhythms that are the most common cause of sudden cardiac arrest (SCA), according to the US National Heart, Lung and Blood Institute (Bethesda, MD, USA). Certain diseases and conditions that can lead to SCA include heart disease, inherited disorders, and structural changes in the heart due to infection or congenital heart disease. Most people who have SCA die from it, often within minutes. Rapid treatment with a defibrillator can save lives.
Related Links:
Zoll Medical Corporation
US National Heart, Lung and Blood Institute
The LifeVest is a wearable defibrillator, which unlike an implantable cardioverter defibrillator (ICD) is worn on the body (under clothing), rather than implanted into it. Weighing less than one kilogram, the device consists of two main components: an electrode belt and vest-like garment that surround the patient’s chest, and a monitor that the patient wears around the waist. The pediatric device is intended only for children weighing at least 18 kg and with a chest size of 66 cm or more, which is about the size of an average eight year old.
The device continuously monitors the patient's heart using dry, non-adhesive sensing electrodes that detect abnormal heart rhythms. If such a life-threatening cardiac rhythm is detected, the device alerts the patient prior to delivering a shock, thus allowing a conscious patient to postpone the treatment shock. If, on the other hand, the patient is unconscious, the device releases a special gel over the therapy electrodes and delivers an electrical shock to restore normal rhythm.
The LifeVest Wearable Cardioverter Defibrillator is a product of Zoll Medical Corporation (Zoll; Chelmsford, MA, USA), and has been approved by the US Food and Drug Administration (FDA) for children who are at risk for sudden cardiac arrest, but are not candidates for an ICD due to certain medical conditions or lack of parental consent. The device was previously approved in 2001 for patients 18 years of age and older.
“The pediatric medical community is often forced to use adult devices off-label without appropriate labeling or instructions for use in pediatric patients,” said Vasum Peiris, MD, MPH, chief medical officer of pediatrics and special populations in the FDA Center for Devices and Radiological Health (CDRH). “Doctors now have important information that may help them safely prescribe this life-saving device to young patients who may benefit from the device.”
Ventricular fibrillation (VF) and ventricular tachycardia (VT) are life-threatening abnormal heart rhythms that are the most common cause of sudden cardiac arrest (SCA), according to the US National Heart, Lung and Blood Institute (Bethesda, MD, USA). Certain diseases and conditions that can lead to SCA include heart disease, inherited disorders, and structural changes in the heart due to infection or congenital heart disease. Most people who have SCA die from it, often within minutes. Rapid treatment with a defibrillator can save lives.
Related Links:
Zoll Medical Corporation
US National Heart, Lung and Blood Institute
Read the full article by registering today, it's FREE!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
- Free digital version edition of HospiMedica International sent by email on regular basis
- Free print version of HospiMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of HospiMedica International in digital format
- Free HospiMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Critical Care News
- Intranasal Spray to Prevent Illnesses from Respiratory Viruses
- Gut Bacteria from Amphibians and Reptiles Show Complete Tumor Elimination
- High-Dose Inhaled Nitric Oxide Emerges as Promising Antimicrobial Therapy
- AI Risk Prediction Tool Improves Treatment of Cancer Patients after Heart Attack
- Glowing Bacterial Sensors Could Improve Detection of Gut Illness
- Innovative ‘Poop Pills’ Dramatically Improve Cancer Treatment

- New Nanomaterial Kills Cancer Cells While Sparring Healthy Tissues
- AI Model Accurately Predicts Neurological Recovery After Cardiac Arrest
- Battery-Free Nano-Sensors Pave Way for Next-Generation Wearables
- Imaging Technology Detects Early Signs of Cardiovascular Risk Through Skin
- New Therapeutic Approach Marks Breakthrough in Pediatric Heart Disease
- AI Model Accurately Identifies Prediabetics Using Only ECG Data
- Injectable Disease-Fighting Nanorobots to Improve Precision Cancer Therapy
- Web-Based Tool Enables Early Detection and Prevention of Chronic Kidney Disease
- Tiny Sensor to Transform Head Injury Detection
- Bacterial Behavior Breakthrough to Improve Infection Prevention in Biomedical Devices
Channels
Artificial Intelligence
view channelSurgical Techniques
view channel
New Classification System Brings Clarity to Brain Tumor Surgery Decisions
Low-grade brain tumors known as IDH-mutant gliomas (CNS WHO grade 2) are life-threatening despite their slow growth. Surgeons must balance maximal tumor removal against the risk of neurological deficits,... Read more
Boengineered Tissue Offers New Hope for Secondary Lymphedema Treatment
The rising global incidence of cancer has led to an increasing number of surgeries involving lymph node removal. While these procedures are critical for cancer staging and preventing metastatic spread,... Read morePatient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read moreFirst-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel
Medtronic and Mindray Expand Strategic Partnership to Ambulatory Surgery Centers in the U.S.
Mindray North America and Medtronic have expanded their strategic partnership to bring integrated patient monitoring solutions to ambulatory surgery centers across the United States. The collaboration... Read more
FDA Clearance Expands Robotic Options for Minimally Invasive Heart Surgery
Cardiovascular disease remains the world’s leading cause of death, with nearly 18 million fatalities each year, and more than two million patients undergo open-heart surgery annually, most involving sternotomy.... Read more
WHX in Dubai (formerly Arab Health) to debut specialised Biotech & Life Sciences Zone as sector growth accelerates globally
World Health Expo (WHX) in Dubai, formerly Arab Health, which takes place from 9-12 February 2026 at the Dubai Exhibition Centre (DEC), has officially announced the launch of a new dedicated Biotech &... Read more








